Cargando…

Hypothesis about Transdifferentiation As Backbone of Malignancy

BACKGROUND: Cancer is mainly watched through the prism of random mutations and related corruption of signaling pathways. However, it would seem puzzling to explain the tumor organization, pugnacity and steady evolution of the tumorous disease and, moreover, a systematic ascendancy over the healthy t...

Descripción completa

Detalles Bibliográficos
Autor principal: Piechowski, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474902/
https://www.ncbi.nlm.nih.gov/pubmed/28674676
http://dx.doi.org/10.3389/fonc.2017.00126
_version_ 1783244520488435712
author Piechowski, Jean
author_facet Piechowski, Jean
author_sort Piechowski, Jean
collection PubMed
description BACKGROUND: Cancer is mainly watched through the prism of random mutations and related corruption of signaling pathways. However, it would seem puzzling to explain the tumor organization, pugnacity and steady evolution of the tumorous disease and, moreover, a systematic ascendancy over the healthy tissues, only through stochastic genomic alterations. MALIGNANCY SPECIFIC PROPERTIES: Considering the core characteristics of cancer cells, it appears that two major sets of properties are emerging, corresponding to well-identified physiological phenotypes, i.e., (1) the trophoblastic logistical functions for cell survival, protection, expansion, migration, and host-tissue conditioning for angiogenesis and immune tolerance and (2) the sexual functions for genome maintenance. To explain the resurgence of these trophoblastic and sexual phenotypes, a particular cell reprogramming, to be called “malignant transdifferentiation” in view of its key role in the precancer-to-cancer shift, appears to be a convincing hypothesis. PERSPECTIVES: The concept of malignant transdifferentiation, in addition to oncogenic mutations, would determine a more rational approach of oncogenesis and would open so far unexplored ways of therapeutic actions. Indeed, the trophoblastic phenotype would be a good candidate for therapeutic purposes because, on the one hand, it covers numerous properties that all are vital for the tumor, and on the other hand, it can be targeted with potentially no risk of affecting the healthy tissues as it is not expressed there after birth.
format Online
Article
Text
id pubmed-5474902
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54749022017-07-03 Hypothesis about Transdifferentiation As Backbone of Malignancy Piechowski, Jean Front Oncol Oncology BACKGROUND: Cancer is mainly watched through the prism of random mutations and related corruption of signaling pathways. However, it would seem puzzling to explain the tumor organization, pugnacity and steady evolution of the tumorous disease and, moreover, a systematic ascendancy over the healthy tissues, only through stochastic genomic alterations. MALIGNANCY SPECIFIC PROPERTIES: Considering the core characteristics of cancer cells, it appears that two major sets of properties are emerging, corresponding to well-identified physiological phenotypes, i.e., (1) the trophoblastic logistical functions for cell survival, protection, expansion, migration, and host-tissue conditioning for angiogenesis and immune tolerance and (2) the sexual functions for genome maintenance. To explain the resurgence of these trophoblastic and sexual phenotypes, a particular cell reprogramming, to be called “malignant transdifferentiation” in view of its key role in the precancer-to-cancer shift, appears to be a convincing hypothesis. PERSPECTIVES: The concept of malignant transdifferentiation, in addition to oncogenic mutations, would determine a more rational approach of oncogenesis and would open so far unexplored ways of therapeutic actions. Indeed, the trophoblastic phenotype would be a good candidate for therapeutic purposes because, on the one hand, it covers numerous properties that all are vital for the tumor, and on the other hand, it can be targeted with potentially no risk of affecting the healthy tissues as it is not expressed there after birth. Frontiers Media S.A. 2017-06-19 /pmc/articles/PMC5474902/ /pubmed/28674676 http://dx.doi.org/10.3389/fonc.2017.00126 Text en Copyright © 2017 Piechowski. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Piechowski, Jean
Hypothesis about Transdifferentiation As Backbone of Malignancy
title Hypothesis about Transdifferentiation As Backbone of Malignancy
title_full Hypothesis about Transdifferentiation As Backbone of Malignancy
title_fullStr Hypothesis about Transdifferentiation As Backbone of Malignancy
title_full_unstemmed Hypothesis about Transdifferentiation As Backbone of Malignancy
title_short Hypothesis about Transdifferentiation As Backbone of Malignancy
title_sort hypothesis about transdifferentiation as backbone of malignancy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474902/
https://www.ncbi.nlm.nih.gov/pubmed/28674676
http://dx.doi.org/10.3389/fonc.2017.00126
work_keys_str_mv AT piechowskijean hypothesisabouttransdifferentiationasbackboneofmalignancy